This is an open-label, phase I/II study of duvelisib in combination with Venetoclax for patients with relapsed/refractory NHL. Duvelisib is an FDA approved, ma…

T-cell-prolymphocytic LeukemiaCutaneous T-Cell Lymphoma Refractory

~Estimated

~$10 – $6,250

Jonsson Comprehensive Cancer CenterNCT06810778

Phase 1

A Phase 1/1b Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of LP-118 in Subjects With Relapsed or Refractory Hematological Malignancies

This is a Phase 1, multi-center, open-label study with a dose-escalation phase (Phase 1a) and a cohort expansion phase (Phase 1b), to evaluate the safety, tole…

Non Hodgkin LymphomaRichter TransformationMultiple Myeloma+10 more

~Estimated

~$10 – $8,750

Newave Pharmaceutical IncNCT04771572